New nanoparticle drug delivery system improves treatment of atherosclerosis
Researchers from Baker Heart and Diabetes Institute have designed and developed a new drug delivery method that could vastly improve the efficacy of a drug to treat atherosclerosis and has the potential to identify and treat other diseases.
The technique, which uses drug-loaded nanoparticles, directly targets the site of atherosclerosis in animal models, improving the uptake of the drug hydroxylpropyl-beta-cyclodextrin (CD) by the cells and significantly lowering cholesterol levels, more effectively than the drug alone.
Currently, high doses of CD are required during the treatment of atherosclerosis, resulting in side effects, including hearing loss, but sustained and local release of this drug-loaded nanoparticle (CDNP), would not only improve the drug’s efficacy, but would likely decrease it. those negative effects.
The study, led by the deputy director of the Baker Institute, professor of basic and translation science Karlheinz Peter, was published in the journal Small this week.
“We know that CD lowers cholesterol levels in dental plaque, but it’s difficult to get the drugs into the needed area, so you need a large amount,” said co-investigator and Baker Institute Laboratory Head, Molecular Imaging and Theranostics Associate Professor Xiaowei Wang.
“We packaged the drug into the nanoparticle, which can be sent directly to the site of the disease. Once there, the drug accumulates and removes cholesterol.
“We already know that CD is an effective treatment for other diseases, including Alzheimer’s disease and Niemann-Pick type C disease, so this technique has the potential to improve treatment efficacy for those diseases as well.”
The nanoparticles have the added benefit of a gas core and fluorescent dye coating, allowing them to be used as a contrast agent for diagnostic imaging, Wang said.
“We can also visualize the nanoparticles on ultrasound, which would be a valuable diagnostic tool, and pop the drug-filled bubble for immediate drug delivery using an ultrasound wave,” she said.
“We believe that these CDNPs provide a platform for diagnostic and therapeutic delivery of anti-atherosclerotic therapy, and that CD carrier platforms such as CDNPs can be used for the co-administration of multiple potent drugs.”
New combination of nanoparticles for atherosclerosis developed
Sourabh Mehta et al, An ultrasound-responsive theranostic cyclodextrin-loaded nanoparticle for multimodal imaging and therapy for atherosclerosis, Small (2022). DOI: 10.1002/smll.202200967
Provided by Baker Heart and Diabetes Institute
Quote: New nanoparticle drug delivery system improves atherosclerosis treatment (2022, June 23) Retrieved June 24, 2022 from https://phys.org/news/2022-06-nanoparticle-drug-delivery-treatment-atherosclerosis.html
This document is copyrighted. Other than fair dealing for personal study or research, nothing may be reproduced without written permission. The content is provided for informational purposes only.